Postmarketing Study Status Reports Need Sponsor Pre-Clearance - PhRMA
This article was originally published in The Tan Sheet
Portions of postmarketing study annual status reports that will be publicly disclosed should be pre-specified by study sponsors, the Pharmaceutical Research & Manufacturers of America suggests to FDA in Feb. 14 comments.
You may also be interested in...
Industry must continue to submit status reports on terminated postmarketing drug studies until FDA concurs the studies will provide no more useful information under a proposed revision to postmarketing study status annual reporting regs published in the Dec. 1 Federal Register.
FDA will ask more directed questions of its advisory committees as a way to narrow the amount of information from NDAs provided to the committees, FDA's Office of Training and Communications Director Nancy Smith, PhD, told the recent Regulatory Affairs Professionals Society annual meeting in Washington, D.C.
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC